NCT05709444 - A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 26, 2022

Primary Completion Date

April 26, 2024

Study Completion Date

April 26, 2024

Conditions

Kidney Disease

Interventions

DRUG

Bremelanotide

Bremelanotide is a cyclic, heptapeptide analog of the endogenous peptide alpha melanocortin stimulating hormone (αMSH).

DRUG

RAAS inhibition therapy

RAS-acting agents are medicines acting on a hormone system that helps to control blood pressure and the amount of fluid in the body.

Trial Locations (9)

Northeast Research Center, LLC, Bethlehem

Brookview Hills Research Associates, LLC, Winston-Salem

Georgia Nephrology, LLC DBA -GA Nephrology Research Institute, Decatur

Georgia Nephrology, LLC [DBA] GA Nephrology Research Institute, Lawrenceville

Nephrotex Research Group, Dallas

Prolator Clinical Research Center, Houston

Clinical Advancement Center, PLLC, San Antonio

California Institute of Renal Research, Chula Vista

California Institute of Renal Research DBA - Balboa Research, La Mesa